| 1 | recent | 22,898 |
| 2 | all-language | 8 |
| 3 | anglo-american | 7 |
| 4 | manufacturer-sponsored | 5 |
| 5 | mideastern | 3 |
| 6 | monumental | 3 |
| 7 | epidemiology-based | 2 |
| 8 | fixed-feature | 2 |
| 9 | proteinogram | 2 |
| 10 | quinquennial | 2 |
| 11 | 1973.the | 1 |
| 12 | 3.8+/-0.8 | 1 |
| 13 | 5.99±4.76 | 1 |
| 14 | 7+/-1.5 | 1 |
| 15 | 73±4.8 | 1 |
| 16 | academic-initiated | 1 |
| 17 | age=43+/-5 | 1 |
| 18 | age≥10 | 1 |
| 19 | age≥45 | 1 |
| 20 | age≥50 | 1 |
| 21 | cgmh | 1 |
| 22 | children≤2 | 1 |
| 23 | costly.eight | 1 |
| 24 | environment-development | 1 |
| 25 | first-light | 1 |
| 26 | form-quantitative | 1 |
| 27 | forth-coming | 1 |
| 28 | hiv/sti-associated | 1 |
| 29 | hypothesis/ | 1 |
| 30 | individuals≥70 | 1 |
| 31 | inter-pandemic | 1 |
| 32 | knowledge-base | 1 |
| 33 | magnetometric | 1 |
| 34 | methodologically-stringent | 1 |
| 35 | non-bleaching | 1 |
| 36 | non-eastern | 1 |
| 37 | non-mutually | 1 |
| 38 | patients≥50 | 1 |
| 39 | patients≥65 | 1 |
| 40 | patients≥75 | 1 |
| 41 | persons≥18 | 1 |
| 42 | post-dcct | 1 |
| 43 | pre-recession | 1 |
| 44 | prestigeous | 1 |
| 45 | pyridinic-nitrogen | 1 |
| 46 | sd-scored | 1 |
| 47 | six-and-a-half | 1 |
| 48 | spondyloarthitis | 1 |
| 49 | s···s-s···s | 1 |
| 50 | transcripts.the | 1 |
| 51 | trials-both | 1 |
| 52 | women≤45 | 1 |
| 53 | women≥30 | 1 |
| 1 | 1973.the | 1 |
| 2 | 3.8+/-0.8 | 1 |
| 3 | 5.99±4.76 | 1 |
| 4 | 7+/-1.5 | 1 |
| 5 | 73±4.8 | 1 |
| 6 | academic-initiated | 1 |
| 7 | age=43+/-5 | 1 |
| 8 | age≥10 | 1 |
| 9 | age≥45 | 1 |
| 10 | age≥50 | 1 |
| 11 | all-language | 8 |
| 12 | anglo-american | 7 |
| 13 | cgmh | 1 |
| 14 | children≤2 | 1 |
| 15 | costly.eight | 1 |
| 16 | environment-development | 1 |
| 17 | epidemiology-based | 2 |
| 18 | first-light | 1 |
| 19 | fixed-feature | 2 |
| 20 | form-quantitative | 1 |
| 21 | forth-coming | 1 |
| 22 | hiv/sti-associated | 1 |
| 23 | hypothesis/ | 1 |
| 24 | individuals≥70 | 1 |
| 25 | inter-pandemic | 1 |
| 26 | knowledge-base | 1 |
| 27 | magnetometric | 1 |
| 28 | manufacturer-sponsored | 5 |
| 29 | methodologically-stringent | 1 |
| 30 | mideastern | 3 |
| 31 | monumental | 3 |
| 32 | non-bleaching | 1 |
| 33 | non-eastern | 1 |
| 34 | non-mutually | 1 |
| 35 | patients≥50 | 1 |
| 36 | patients≥65 | 1 |
| 37 | patients≥75 | 1 |
| 38 | persons≥18 | 1 |
| 39 | post-dcct | 1 |
| 40 | pre-recession | 1 |
| 41 | prestigeous | 1 |
| 42 | proteinogram | 2 |
| 43 | pyridinic-nitrogen | 1 |
| 44 | quinquennial | 2 |
| 45 | recent | 22,898 |
| 46 | sd-scored | 1 |
| 47 | six-and-a-half | 1 |
| 48 | spondyloarthitis | 1 |
| 49 | s···s-s···s | 1 |
| 50 | transcripts.the | 1 |
| 51 | trials-both | 1 |
| 52 | women≤45 | 1 |
| 53 | women≥30 | 1 |
| 1 | hypothesis/ | 1 |
| 2 | age≥10 | 1 |
| 3 | women≥30 | 1 |
| 4 | age≥50 | 1 |
| 5 | patients≥50 | 1 |
| 6 | individuals≥70 | 1 |
| 7 | children≤2 | 1 |
| 8 | age=43+/-5 | 1 |
| 9 | 7+/-1.5 | 1 |
| 10 | women≤45 | 1 |
| 11 | age≥45 | 1 |
| 12 | patients≥65 | 1 |
| 13 | patients≥75 | 1 |
| 14 | 5.99±4.76 | 1 |
| 15 | 3.8+/-0.8 | 1 |
| 16 | 73±4.8 | 1 |
| 17 | persons≥18 | 1 |
| 18 | inter-pandemic | 1 |
| 19 | magnetometric | 1 |
| 20 | sd-scored | 1 |
| 21 | manufacturer-sponsored | 5 |
| 22 | epidemiology-based | 2 |
| 23 | hiv/sti-associated | 1 |
| 24 | academic-initiated | 1 |
| 25 | all-language | 8 |
| 26 | 1973.the | 1 |
| 27 | transcripts.the | 1 |
| 28 | fixed-feature | 2 |
| 29 | knowledge-base | 1 |
| 30 | form-quantitative | 1 |
| 31 | six-and-a-half | 1 |
| 32 | non-bleaching | 1 |
| 33 | forth-coming | 1 |
| 34 | cgmh | 1 |
| 35 | trials-both | 1 |
| 36 | quinquennial | 2 |
| 37 | monumental | 3 |
| 38 | proteinogram | 2 |
| 39 | anglo-american | 7 |
| 40 | pyridinic-nitrogen | 1 |
| 41 | pre-recession | 1 |
| 42 | non-eastern | 1 |
| 43 | mideastern | 3 |
| 44 | spondyloarthitis | 1 |
| 45 | prestigeous | 1 |
| 46 | s···s-s···s | 1 |
| 47 | post-dcct | 1 |
| 48 | costly.eight | 1 |
| 49 | first-light | 1 |
| 50 | recent | 22,898 |
| 51 | methodologically-stringent | 1 |
| 52 | environment-development | 1 |
| 53 | non-mutually | 1 |